Agios Pharmaceuticals Inc (NASDAQ:AGIO) Receives Consensus Rating of “Buy” from Brokerages

Agios Pharmaceuticals Inc (NASDAQ:AGIO) has earned an average rating of “Buy” from the seventeen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $68.77.

A number of research firms have issued reports on AGIO. ValuEngine lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. Canaccord Genuity restated a “buy” rating and set a $72.00 price objective on shares of Agios Pharmaceuticals in a research note on Friday, July 31st. Needham & Company LLC assumed coverage on Agios Pharmaceuticals in a research note on Thursday, July 30th. They set a “buy” rating and a $71.00 price objective on the stock. Guggenheim increased their target price on Agios Pharmaceuticals from $60.00 to $66.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 15th.

Hedge funds have recently modified their holdings of the stock. Amundi Pioneer Asset Management Inc. raised its position in shares of Agios Pharmaceuticals by 3,306.0% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 143,050 shares of the biopharmaceutical company’s stock worth $9,648,000 after acquiring an additional 138,850 shares in the last quarter. BlackRock Inc. grew its holdings in Agios Pharmaceuticals by 16.3% during the first quarter. BlackRock Inc. now owns 4,529,580 shares of the biopharmaceutical company’s stock worth $160,709,000 after acquiring an additional 636,186 shares during the period. Arizona State Retirement System acquired a new position in Agios Pharmaceuticals during the first quarter worth about $502,000. New York State Common Retirement Fund grew its holdings in Agios Pharmaceuticals by 19.9% during the first quarter. New York State Common Retirement Fund now owns 109,604 shares of the biopharmaceutical company’s stock worth $3,889,000 after acquiring an additional 18,204 shares during the period. Finally, Rhumbline Advisers grew its holdings in Agios Pharmaceuticals by 31.5% during the first quarter. Rhumbline Advisers now owns 63,867 shares of the biopharmaceutical company’s stock worth $2,266,000 after acquiring an additional 15,281 shares during the period. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Shares of Agios Pharmaceuticals stock traded up $0.52 on Wednesday, hitting $38.80. The company’s stock had a trading volume of 442 shares, compared to its average volume of 549,445. Agios Pharmaceuticals has a 52-week low of $27.77 and a 52-week high of $56.74. The firm has a fifty day moving average price of $41.52 and a 200-day moving average price of $44.93. The company has a market capitalization of $2.65 billion, a P/E ratio of -7.21 and a beta of 1.86.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.36) by $0.05. The company had revenue of $37.30 million for the quarter, compared to analyst estimates of $37.17 million. Agios Pharmaceuticals had a negative net margin of 182.49% and a negative return on equity of 59.71%. The firm’s quarterly revenue was up 42.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.87) EPS. As a group, analysts expect that Agios Pharmaceuticals will post -4.58 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Featured Story: Price-Sales Ratio

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.